shows that the majority of the studies had a point estimate to the right of 0. The 2-sided p value from the sign test is 0.023. In Study 9, the treatment effect in the United States seemed to be substantially better than outside the United States, but in Studies 5, 12, 13, 17, and 21, the treatment effect appeared to be substantially worse in the United States than outside of the United States.
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In the random effects meta-analysis, the estimate of the between-trial variability was 0. The estimate of the mean loghazard ratio was 0.103 with a standard error of 0.035. Thus, the approximate confidence interval is (0.031 to 0.175) and the 2-sided p value for the test of mean zero difference is p ϭ 0.007. Because the estimate of the between-trial variability was zero, the point estimate and estimated standard error from the fixed effect model are identical to those from the random effect model described.
It seems that there may be systematic differences between the treatment effects observed in the United States and non-U.S. regions, with the U.S.-specific treatment effect usually being smaller. Some factors that might contribute to differences in treatment effects between regions include differences in compliance, follow-up, and concomitant medications. There are other possible explanations, and in any particular trial the factors that may attenuate the treatment effect may not be anticipated or even measured. In future trials, if there is a concern that there may be a difference in the treatment effect in the United States versus other countries and the U.S.-specific treatment effect is of interest, there are both issues of design and analysis to consider. An analysis could be planned in the protocol to deal with this possible difference. This could include formal tests for interaction or examination of differences in baseline characteristics or background therapy between regions. Planning for a test for qualitative or quantitative interaction is helpful in some cases, but both tests are known to have low power when the differences are moderate, and this situation may not be totally satisfactory for this purpose. In studies in which a goal of the study is to confirm a global treatment effect and a country-specific treatment effect, there should be a plan to obtain a sufficient amount of information in the country or region of interest, and an analysis should be pre-planned to do so. We read with interest the recent report by Lakkireddy et al. (1) regarding periprocedural dabigatran in patients undergoing atrial fibrillation (AF) ablation. This multicenter study noted a significant increase in bleeding and thromboembolic complications with essentially uninterrupted dabigatran versus uninterrupted warfarin. Their findings emphasize the importance of fully understanding the pharmacokinetics of pharmacologic agents, particularly anticoagulants, which can cause serious complications. Dabigatran possesses several pharmacokinetic properties that are important to safe periprocedural use. These properties predict the potential for increased complications when used in an uninterrupted manner for ablations.
*
1. There is an in vitro heparin-dabigatran interaction (2) . Dabigatran potentiates heparin's antithrombotic properties with quantitatively doubled anticoagulant effect. The increased bleeding complications noted by Lakkireddy et al. (1) suggest that this in vitro interaction very likely occurs in vivo. This interaction is much less apparent with rivaroxaban and apixaban (2). 2. Immediately following hip surgery, dabigatran absorption can be both delayed and reduced (3). Thus, oral dabigatran immediately after an AF ablation may not provide anticoagulation during the immediate post-procedural period. Enoxaparin immediately post-ablation will avoid this anticoagulant lapse until oral absorption of dabigatran occurs. 3. Dabigatran has no direct antidote, so when bleeding complications occur they may be more difficult to treat than those with warfarin.
Based on these pharmacokinetic considerations, we agree it is not appropriate to use dabigatran in a nearly uninterrupted manner. This does not diminish dabigatran's utility when used in an interrupted manner. We have reported the safety of interrupted dabigatran in 123 patients (4) and have subsequently extended our experience to more than 500 patients (40% of whom were on dabigitran pre-ablation) without a single hemorrhagic or thromboembolic complication. As emphasized by Lakkireddy et al. (1), there were significant differences in our use of dabigatran that likely account for the safety and efficacy demonstrated in our series. Heparin administration to patients in whom dabigatran has not been fully interrupted might be expected to lead to increased bleeding complications due to a probable drug-drug interaction and poor absorption post-ablation might lead to increased thromboembolic events. The convenience of standardized oral dosing and elimination of INR monitoring makes dabigatran and other new oral anticoagulants attractive alternates to warfarin for AF ablation patients.
